Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era

Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era

In this week's "Adam's Biotech Scorecard," Adam points out what to look for to get a better sense of the FDA's positions of regulatory flexibility.

CBER Director Vinay Prasad dared to “say no to drugs”

FDA’s Center for Biologics Evaluation and Research Director Vinay Prasad is set to leave the agency for a second time amid controversy.  This episode is available on Spotify, Apple Podcasts, and Youtube. In a March 6 post on X, FDA Commissioner Marty Makary suggested that Prasad’s presence at FDA was a “sabbatical” from his academic career and that he would be returning to his job at the University of California, San Francisco. “Under Richard P…